Tsolakis N, et al. - In this study, researchers sought to determine a clinically useful level of IgE sensitisation for ruling out type-2 asthma. They found that in young asthmatics with IgE antibodies < 0.35 kU_A/L, but not those with IgE < 0.10 kU_A/L, type-2 biomarkers were elevated to a clinically relevant level. Notably, it seemed possible to define non-type 2 asthma via sensitive IgE-antibody measurement.